KTTA
Pasithea Therapeutics Corp.
Biotechnology
Market Cap$18M
5Y Perf.-98.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KTTA vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-45.9%
KTTA vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KTTA | MNMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $18M | $2.04B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-13M | $-238M |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $7M | $258M |
KTTA vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KTTA
MNMD
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Pasithea Therapeuti… (KTTA) | 100 | 1.3 | -98.7% |
| Mind Medicine (Mind… (MNMD) | 100 | 54.1 | -45.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KTTA vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KTTA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Mind Medicine (MindMed) Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
KTTA
Pasithea Therapeutics Corp.
The Income Pick
KTTA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.12
- EPS growth 2.5%
- Lower volatility, beta 1.12, current ratio 6.58x
Best for: income & stability and growth exposure
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the clearest fit if your priority is long-term compounding.
- 5.1% 10Y total return vs KTTA's -98.9%
- +220.3% vs KTTA's -17.2%
- -70.7% ROA vs KTTA's -88.0%, ROIC -389.5% vs -142.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KTTA | 15.2% revenue growth vs MNMD's -96.9% |
| Quality / Margins | KTTA | 2.6% margin vs MNMD's 1.2% |
| Stability / Safety | KTTA | Beta 1.12 vs MNMD's 1.63 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNMD | +220.3% vs KTTA's -17.2% |
| Efficiency (ROA) | MNMD | -70.7% ROA vs KTTA's -88.0%, ROIC -389.5% vs -142.4% |
KTTA vs MNMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGKTTA
KTTAPasithea Therapeutics…
1leads
MNMDMind Medicine (MindMe…
2leads
6 Total Categories
CATEGORYLEADERvs KTTAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KTTA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNMD4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KTTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KTTA and MNMD operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | KTTAPasithea Therapeu… | MNMDMind Medicine (Mi… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$13M | -$191M |
| Net IncomeAfter-tax profit | -$13M | -$238M |
| Free Cash FlowCash after capex | -$12M | -$174M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +85.7% | -163.0% |
KTTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KTTA and MNMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KTTAPasithea Therapeu… | MNMDMind Medicine (Mi… |
|---|---|---|
| Market CapShares × price | $18M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $11M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.06x | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KTTA and MNMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNMD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
KTTA delivers a -97.9% return on equity — every $100 of shareholder capital generates $-98 in annual profit, vs $-102 for MNMD. On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs KTTA's 2/9, reflecting mixed financial health.
| Metric | KTTAPasithea Therapeu… | MNMDMind Medicine (Mi… |
|---|---|---|
| ROE (TTM)Return on equity | -97.9% | -102.5% |
| ROA (TTM)Return on assets | -88.0% | -70.7% |
| ROICReturn on invested capital | -142.4% | -3.9% |
| ROCEReturn on capital employed | -74.2% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$7M | -$258M |
| Cash & Equiv.Liquid assets | $7M | $258M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -21.81x |
MNMD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,493 today (with dividends reinvested), compared to $112 for KTTA. Over the past 12 months, MNMD leads with a +220.3% total return vs KTTA's -17.2%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs KTTA's -51.8% — a key indicator of consistent wealth creation.
| Metric | KTTAPasithea Therapeu… | MNMDMind Medicine (Mi… |
|---|---|---|
| YTD ReturnYear-to-date | -33.2% | +51.7% |
| 1-Year ReturnPast 12 months | -17.2% | +220.3% |
| 3-Year ReturnCumulative with dividends | -88.8% | +510.3% |
| 5-Year ReturnCumulative with dividends | -98.9% | -55.1% |
| 10-Year ReturnCumulative with dividends | -98.9% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -51.8% | +82.7% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KTTA and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
KTTA is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than MNMD's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs KTTA's 38.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KTTAPasithea Therapeu… | MNMDMind Medicine (Mi… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 1.63x |
| 52-Week HighHighest price in past year | $2.06 | $21.09 |
| 52-Week LowLowest price in past year | $0.28 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +38.6% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 61.5 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 459K | 779K |
Evenly matched — KTTA and MNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | KTTAPasithea Therapeu… | MNMDMind Medicine (Mi… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $20.00 |
| # AnalystsCovering analysts | — | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). KTTA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 2 of 6 categories
Loading custom metrics...
KTTA vs MNMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KTTA or MNMD a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KTTA or MNMD?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -55. 1%, compared to -98. 9% for Pasithea Therapeutics Corp. (KTTA). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus KTTA's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KTTA or MNMD?
By beta (market sensitivity over 5 years), Pasithea Therapeutics Corp.
(KTTA) is the lower-risk stock at 1. 12β versus Mind Medicine (MindMed) Inc. 's 1. 63β — meaning MNMD is approximately 45% more volatile than KTTA relative to the S&P 500.
04Which is growing faster — KTTA or MNMD?
On earnings-per-share growth, the picture is similar: Pasithea Therapeutics Corp.
grew EPS 2. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KTTA or MNMD?
Pasithea Therapeutics Corp.
(KTTA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KTTA leads at 0. 0% versus 0. 0% for MNMD. At the gross margin level — before operating expenses — KTTA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KTTA or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KTTA or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Pasithea Therapeutics Corp.
(KTTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Mind Medicine (MindMed) Inc. (MNMD) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KTTA: -98. 9%, MNMD: +512. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KTTA and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.